7 months ago
3
Eli Lilly signed an statement with Cipla, allowing the Indian drugmaker to merchantability its blockbuster weight-loss cause nether a abstracted marque successful the country, the companies said connected Thursday (October 23, 2025)
Under the agreement, Lilly volition manufacture the cause and Cipla volition marketplace it nether the marque sanction Yurpeak, the drugmakers said.
Yurpeak volition beryllium disposable arsenic a once-weekly pre-filled injector pen, aforesaid arsenic Lilly's Mounjaro Kwikpen, allowing healthcare providers to personalise attraction plans to idiosyncratic diligent needs.
The medicine volition beryllium disposable successful six dose strengths -2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg and volition beryllium priced the aforesaid arsenic Mounjaro.
Lilly began selling Mounjaro successful India successful precocious March for diabetes and obesity successful 2.5 mg and 5 mg vials, earlier getting India cause regulator's support for the Kwikpen instrumentality successful June. The drug's income much than doubled wrong months of its launch.
Tirzepatide belongs to a people of therapies known arsenic GLP-1 receptor agonists that assistance power humor sweetener and slow digestion, making radical consciousness fuller for longer.
